Compare Herbalife Nutrition Ltd (HLF) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Herbalife Nutrition Ltd vs Zimmer Biomet Holdings Inc — how do they compare? Herbalife Nutrition Ltd trades at $13.03 (market cap $1.34B), while Zimmer Biomet Holdings Inc trades at $89.19 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 12.6× Herbalife Nutrition Ltd's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Herbalife Nutrition Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Herbalife Nutrition Ltd for 43 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| HLF | ZBH | |
|---|---|---|
Market Cap | $1.34B | $16.95B |
Volume | 1,589,457 | 2,505,240 |
Sector | Consumer Staples | Health |
52-Week High | $19.96 | $103.98 |
52-Week Low | $7.75 | $79.58 |
Typical Hold Time | 43 Days | 89 Days |
Enterprise Value | $3.18B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Herbalife (HLF) trades at $12.86, up 1.62% on the day, with a bullish technical signal and a consensus analyst price target of $19.00 implying significant upside. The company reported Q2 2026 EPS of $0.51, missing expectations, but reaffirmed full-year 2026 guidance. Financials show a net income margin of 3.16% for 2025, with a low P/E of 8.22 and P/S of 0.26, suggesting potential undervaluation. Recent news includes a $250 million share repurchase authorization and a planned CEO transition effective October 31, 2026.
The outlook for HLF is cautiously optimistic, with valuation metrics and analyst sentiment supporting a bullish case, but risks include recent earnings misses, high debt levels, and ongoing leadership changes. The stock presents a value opportunity if the company can execute on its growth and margin expansion plans while managing its leverage.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Herbalife Nutrition Ltd
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
